OncoMatch/Clinical Trials/NCT02332668
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Is NCT02332668 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Pembrolizumab for melanoma.
Treatment: Pembrolizumab — Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back after it had responded to previous treatment (responded means it stopped growing, gets smaller, or disappeared) * Refractory, which means cancer did not respond to previous treatment Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away. With Amendment 8, enrolment of participants with solid tumours and participants 6 months to under 12 years old with melanoma were closed. Enrolment of participants 12-18 years old with melanoma continues. Enrolment of participants who have tumours with specific traits (microsatellite-instability-high (MSI-H), and tumour-mutational burden-high ≥10 mutation/Mb (TMB-H)) also continues.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Melanoma
Hodgkin Lymphoma
Tumor Agnostic
Biomarker criteria
Required: PD-L1 (CD274) positive (positive)
Disease stage
Required: Stage III, IV
locally-advanced, or metastatic solid malignancy or lymphoma that is incurable and has failed prior standard therapy
Demographics
Prior therapy
Must have received: standard therapy
has failed prior standard therapy, or for which no standard therapy exists, or for which no standard therapy is considered appropriate
Cannot have received: anti-PD-1 therapy
Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand 1 (anti-PD-L1), anti-PD-L2 agent, or any agent directed to another stimulatory or inhibitory T-cell receptor (eg, cytotoxic lymphocyte associated protein-4 [CTLA-4], OX-40, CD137)
Cannot have received: systemic anti-cancer therapy
Exception: within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent
Prior systemic anti-cancer therapy including investigational agent within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent
Cannot have received: radiotherapy
Exception: within 2 weeks of start of study treatment
Prior radiotherapy within 2 weeks of start of study treatment
Cannot have received: investigational agent
Exception: within 4 weeks of the date of allocation/randomization
participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the date of allocation/randomization
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Demonstrate adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Call for Information (Investigational Site 0019) · Aurora, Colorado
- Call for Information (Investigational Site 0026) · Boston, Massachusetts
- Call for Information (Investigational Site 0031) · New York, New York
- Call for Information (Investigational Site 0070) · Fargo, North Dakota
- Call for Information (Investigational Site 0032) · Cincinnati, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02332668 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-PD-1 therapy, systemic anti-cancer therapy, radiotherapy disqualifies patients from enrollment.
Does this trial require CD274?
Yes, CD274 positive is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Is there an age limit?
Yes. Patients must be 17 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify